Address: Gyömrői út 19-21, H-1103 Budapest, Hungary,Hungary
Tel: (+36) 1-431-4000
Web: http://www.richter.hu/HU/Pages/home.aspx
Gedeon Richter Plc. is a Hungarian-controlled Central-Eastern European multinational pharmaceutical company. The parent company and its manufacturing subsidiaries in four countries combine to form the region’s leading pharmaceutical manufacturing group. The Company’s products are available, through its own distribution network, to the inhabitants of some 100 different countries.
Our activity includes research, development, manufacture and marketing of human finished drugs, active substances and intermediates.
Gedeon Richter Benelux’s Isabelle de Walsche gives an update on the affiliate’s progress towards becoming a reference player in women’s health, looks back on some of her achievements over 11…
Isabelle De Walsche, managing director of Gedeon Richter in Belgium, the Netherlands, and Luxembourg gives an update on the affiliate’s development since its establishment in 2012. De Waslche goes on…
With a footprint of over 20 years in the Czech Republic, Gedeon Richter’s affiliate here is a key pillar to the company’s success in the Central Eastern European region. Corina…
Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s…
Andras Gizur, president China & APAC for Gedeon Richter, shares his insights on the current market environment in China following the spate of recent healthcare reforms, the exciting innovations Gedeon…
Emmanuel Eumont, general manager of Gedeon Richter France, discusses the group’s leading position in women’s health, its external growth strategy, notably through the acquisition of Finox Biotech in 2016, and…
Corina Croitoru of Gedeon Richter Slovakia discusses GR’s footprint in the country, the affiliate’s main growth drivers, the importance of women’s health, and the intricacies of market access. Gedeon Richter’s…
Country Manager Giovanna Labbate talks how Gedeon Richter aims to become the point of reference for women’s health in Italy, the successful launch of ESMYA, and the establishment of the…
Isabelle de Walsche, Managing Director of Gedeon Richter Benelux, provides us with an update on the development of this striving and ambitious player in the women’s healthcare field and shares…
The president of Gedeon Richter France and CEO of PregLem, a Swiss-based biotech company acquired by Gedeon Richter in 2010, discusses the exciting synergies that have emerged from this partnership…
Mr. Gyürüsi, Gedeon Richter is a 111-year-old company that is synonymous with the Central and Eastern European pharma industry. The business has been present in Czechoslovakia since 1956, and has…
Since establishing Gedeon Richter’s operations here 16 years ago, you’ve been involved in the full array of the pharmaceutical spectrum, from R&D, sourcing API, sales and marketing of finished products,…
Gedeon Richter’s Erik Bogsch discusses the company’s 100th anniversary, it’s growing international footprint and the future of Hungarian pharma. Gedeon Richter is known to be the flagship pharmaceutical company…
A roundup of some of the biggest healthcare and pharma news from China including the exclusion of Pfizer’s Paxlovid from the country’s national insurance coverage, CanSino’s promising mRNA booster trial…
A roundup of some of the biggest healthcare and pharma news from China, including the country’s struggle with a rampant COVID-19 outbreak and the external concern that surrounds it, China…
Writing in the special December 2022 edition of DIA’s Global Forum magazine – which focuses exclusively on decentralised clinical trials – on behalf of the DIA China Digital Health Community…
Accestra Consulting’s Zhao Lu* looks back on a year in which China’s Center for Disease Evaluation (CDE) rejected a record-breaking number of drug applications, explores some of the main reasons…
China’s strict ‘dynamic COVID-zero’ policy, relying on lockdowns, mass-testing and border controls to stamp out COVID-19 outbreaks wherever they appear, has undoubtedly constricted the country’s economic growth and prompted uncommon…
DIA Global Forum’s annual review of new drug approvals in China has shown growth in both the number and types of new drugs approved in China from 2019 through 2021:…
A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR…
Despite the impact of the COVID-19 pandemic and the vagaries of the country’s restrictive ‘dynamic zero COVID’ policy, the Chinese pharmaceutical industry is expected to continue its remarkable trajectory up…
China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell…
A selection of the latest stories from Chinese pharma, including Novartis’ bet that the country will become its second biggest market by 2024 through the introduction of 50 new drugs,…
Some of the most significant recent stories emanating from Chinese healthcare and life sciences, including why the development of a domestic mRNA COVID vaccine – widely acknowledged as an essential…
Due in part to an increasingly encouraging regulatory environment, China continues to strive for progress in cell and gene therapies (CGT). In fact, according to a 2021 Nature study, CAR…
See our Cookie Privacy Policy Here
